Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation

Alfred Asante-Korang, Jennifer Carapellucci, Diane Krasnopero, Abigail Doyle, Brian Brown, Ernest Amankwah

Research output: Contribution to journalArticle

Abstract

There are only a few reports of successful use of mammalian target of rapamycin (mTORI) as primary immunosuppression in pediatric heart transplantation. Compared to calcineurin inhibitors, mTORI have less side effects, especially nephrotoxicity, infections, and malignancies. A retrospective study was conducted at our institution of all 170 heart transplants from 1995 to 2015. Nineteen patients were switched from tacrolimus (n=15) or cyclosporin (n=4) to everolimus (n=4) or sirolimus (n=15) due to nephrotoxicity (n=5), malignancy (n=8), EBV viremia/reactive plasmacytic changes (n=5), and immune hemolytic anemia (n=1). We monitored for rejection, infection, BUN, creatinine, hyperlipidemia, EBV and CMV copies, CBC, cardiac allograft vasculopathy (CAV), and death. Target trough levels of sirolimus and everolimus were 4-10. Four treatment failures included debilitating rash, bone marrow suppression, recurrent rejection, and renal transplantation. There were no deaths. One patient had recurrent rejection episodes, and tacrolimus was reinitiated. One patient with preexisting CAV underwent heart retransplantation. One patient, who was treated for PTLD, transformed to CD30+ Hodgkins disease, and was treated with brentuximab. There were three acute rejection episodes. Median creatinine preswitch was higher 0.82 than postswitch 0.78 (P=.016). Median eGFR was lower preswitch, 75.6, than postswitch, 91.2 (P=.0004). These results indicate that conversion to mTORI as primary immunosuppression may be safely accomplished in some pediatric heart transplant patients.

Original languageEnglish (US)
Article numbere13054
JournalClinical Transplantation
Volume31
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Sirolimus
Heart Transplantation
Immunosuppressive Agents
Pediatrics
Pharmaceutical Preparations
Tacrolimus
Human Herpesvirus 4
Immunosuppression
Allografts
Creatinine
Transplants
Viremia
Blood Urea Nitrogen
Hemolytic Anemia
Infection
Exanthema
Hyperlipidemias
Treatment Failure
Hodgkin Disease
Kidney Transplantation

Keywords

  • calcineurin inhibitors
  • conversion
  • cyclosporin
  • everolimus
  • immunosuppression
  • mTOR inhibitors
  • sirolimus
  • tacrolimus

ASJC Scopus subject areas

  • Transplantation

Cite this

Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation. / Asante-Korang, Alfred; Carapellucci, Jennifer; Krasnopero, Diane; Doyle, Abigail; Brown, Brian; Amankwah, Ernest.

In: Clinical Transplantation, Vol. 31, No. 10, e13054, 01.10.2017.

Research output: Contribution to journalArticle

Asante-Korang, Alfred ; Carapellucci, Jennifer ; Krasnopero, Diane ; Doyle, Abigail ; Brown, Brian ; Amankwah, Ernest. / Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation. In: Clinical Transplantation. 2017 ; Vol. 31, No. 10.
@article{b80a0e25eeb44516a373f3e4e230a27e,
title = "Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation",
abstract = "There are only a few reports of successful use of mammalian target of rapamycin (mTORI) as primary immunosuppression in pediatric heart transplantation. Compared to calcineurin inhibitors, mTORI have less side effects, especially nephrotoxicity, infections, and malignancies. A retrospective study was conducted at our institution of all 170 heart transplants from 1995 to 2015. Nineteen patients were switched from tacrolimus (n=15) or cyclosporin (n=4) to everolimus (n=4) or sirolimus (n=15) due to nephrotoxicity (n=5), malignancy (n=8), EBV viremia/reactive plasmacytic changes (n=5), and immune hemolytic anemia (n=1). We monitored for rejection, infection, BUN, creatinine, hyperlipidemia, EBV and CMV copies, CBC, cardiac allograft vasculopathy (CAV), and death. Target trough levels of sirolimus and everolimus were 4-10. Four treatment failures included debilitating rash, bone marrow suppression, recurrent rejection, and renal transplantation. There were no deaths. One patient had recurrent rejection episodes, and tacrolimus was reinitiated. One patient with preexisting CAV underwent heart retransplantation. One patient, who was treated for PTLD, transformed to CD30+ Hodgkins disease, and was treated with brentuximab. There were three acute rejection episodes. Median creatinine preswitch was higher 0.82 than postswitch 0.78 (P=.016). Median eGFR was lower preswitch, 75.6, than postswitch, 91.2 (P=.0004). These results indicate that conversion to mTORI as primary immunosuppression may be safely accomplished in some pediatric heart transplant patients.",
keywords = "calcineurin inhibitors, conversion, cyclosporin, everolimus, immunosuppression, mTOR inhibitors, sirolimus, tacrolimus",
author = "Alfred Asante-Korang and Jennifer Carapellucci and Diane Krasnopero and Abigail Doyle and Brian Brown and Ernest Amankwah",
year = "2017",
month = "10",
day = "1",
doi = "10.1111/ctr.13054",
language = "English (US)",
volume = "31",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation

AU - Asante-Korang, Alfred

AU - Carapellucci, Jennifer

AU - Krasnopero, Diane

AU - Doyle, Abigail

AU - Brown, Brian

AU - Amankwah, Ernest

PY - 2017/10/1

Y1 - 2017/10/1

N2 - There are only a few reports of successful use of mammalian target of rapamycin (mTORI) as primary immunosuppression in pediatric heart transplantation. Compared to calcineurin inhibitors, mTORI have less side effects, especially nephrotoxicity, infections, and malignancies. A retrospective study was conducted at our institution of all 170 heart transplants from 1995 to 2015. Nineteen patients were switched from tacrolimus (n=15) or cyclosporin (n=4) to everolimus (n=4) or sirolimus (n=15) due to nephrotoxicity (n=5), malignancy (n=8), EBV viremia/reactive plasmacytic changes (n=5), and immune hemolytic anemia (n=1). We monitored for rejection, infection, BUN, creatinine, hyperlipidemia, EBV and CMV copies, CBC, cardiac allograft vasculopathy (CAV), and death. Target trough levels of sirolimus and everolimus were 4-10. Four treatment failures included debilitating rash, bone marrow suppression, recurrent rejection, and renal transplantation. There were no deaths. One patient had recurrent rejection episodes, and tacrolimus was reinitiated. One patient with preexisting CAV underwent heart retransplantation. One patient, who was treated for PTLD, transformed to CD30+ Hodgkins disease, and was treated with brentuximab. There were three acute rejection episodes. Median creatinine preswitch was higher 0.82 than postswitch 0.78 (P=.016). Median eGFR was lower preswitch, 75.6, than postswitch, 91.2 (P=.0004). These results indicate that conversion to mTORI as primary immunosuppression may be safely accomplished in some pediatric heart transplant patients.

AB - There are only a few reports of successful use of mammalian target of rapamycin (mTORI) as primary immunosuppression in pediatric heart transplantation. Compared to calcineurin inhibitors, mTORI have less side effects, especially nephrotoxicity, infections, and malignancies. A retrospective study was conducted at our institution of all 170 heart transplants from 1995 to 2015. Nineteen patients were switched from tacrolimus (n=15) or cyclosporin (n=4) to everolimus (n=4) or sirolimus (n=15) due to nephrotoxicity (n=5), malignancy (n=8), EBV viremia/reactive plasmacytic changes (n=5), and immune hemolytic anemia (n=1). We monitored for rejection, infection, BUN, creatinine, hyperlipidemia, EBV and CMV copies, CBC, cardiac allograft vasculopathy (CAV), and death. Target trough levels of sirolimus and everolimus were 4-10. Four treatment failures included debilitating rash, bone marrow suppression, recurrent rejection, and renal transplantation. There were no deaths. One patient had recurrent rejection episodes, and tacrolimus was reinitiated. One patient with preexisting CAV underwent heart retransplantation. One patient, who was treated for PTLD, transformed to CD30+ Hodgkins disease, and was treated with brentuximab. There were three acute rejection episodes. Median creatinine preswitch was higher 0.82 than postswitch 0.78 (P=.016). Median eGFR was lower preswitch, 75.6, than postswitch, 91.2 (P=.0004). These results indicate that conversion to mTORI as primary immunosuppression may be safely accomplished in some pediatric heart transplant patients.

KW - calcineurin inhibitors

KW - conversion

KW - cyclosporin

KW - everolimus

KW - immunosuppression

KW - mTOR inhibitors

KW - sirolimus

KW - tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=85030676601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030676601&partnerID=8YFLogxK

U2 - 10.1111/ctr.13054

DO - 10.1111/ctr.13054

M3 - Article

VL - 31

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 10

M1 - e13054

ER -